-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons within the substantia nigra accompanied by Lewy body inclusions and α-synapsin deposition
.
Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease, with an incidence of 14 per 100,000 people, and men are more susceptible than women
The clinical course of PD is variable and can include motor and nonmotor symptoms
.
Among non-motor symptoms, psychosis has a significant clinical impact on PD patients and represents a major challenge in PD treatment
Quality of Life
Unfortunately, given the intricate relationship between antiparkinsonian drugs, antipsychotics, and the clinical course of the disease, the treatment of PDP remains a challenge for clinicians
.
The use of antipsychotics is the usual initial strategy for the treatment of PDP; however, this treatment has been reported to have relatively poor efficacy and a possible risk of death from cardiovascular disease, especially with typical antipsychotics
This treatment has relatively poor efficacy and may have a risk of death from cardiovascular disease, especially with typical antipsychotics
Using the Rochester Epidemiology Project, they studied Parkinson's disease in Olmsted County, Minnesota (1991-2010)
.
Movement disorder specialists reviewed electronic medical records and applied diagnostic criteria to PD
diagnosis
They identified 669 cases of Parkinson's disease; 297 patients were clinically diagnosed with Parkinson's disease
.
114/297 (38.
The incidence of Parkinson's disease psychosis (PDP) was 4.
28/100 person-years
.
Compared with PD patients, PDP patients had a 71% increased risk of death
Among Parkinson's disease patients without psychosis, men had a 73.
4% increased risk of death compared with women, while no significant gender differences were observed between men and women with PDP
.
Of the 114 patients diagnosed with psychosis, 59 received antipsychotic medication
The significance of the study is that it found that, compared with PD patients, PDP increased the odds of death
.
Compared with women, men with PD without psychosis had a greater chance of dying; however, among PD patients with psychosis, the odds of death were comparable between men and women
.
Finally, treatment with antipsychotics did not significantly affect survival
.
PDP increases odds of death compared with PD patients
Original source:
Stang CD, Mullan AF, Camerucci E, et al.
Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson Disease (1991–2010).
Leave a comment here
